Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future

By sjmartinez • October 31, 2024

Adam SJ, Buchman TG, Currier JS, Draghia-Akli R, Fessel JP, Higgs ES, Hughes EA, LaVange L, Menetski JP, Read SW, Rosenberg Y, Tressler R; ACTIV Therapeutics-Clinical Working Group. Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future. J Clin Transl Sci. 2024 Oct 15;8(1):e150. doi: 10.1017/cts.2024.178. PMID: 39478782; PMCID: PMC11523022.

Tags: covid-19, Infectious Diseases, lessons learned, master protocol, Publications, Therapeutics, trials

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton[...]

Cluster of Extensively Drug-Resistant Shigella sonnei Carrying blaCTX-M-15 in Los Angeles, California, 2023-2024

Caldera JR, Shaw B, Uslan DZ, Yang S. Cluster of Extensively Drug-Resistant Shigella sonnei Carrying blaCTX-M-15 in Los Angeles, California, 2023-2024. Am J Infect Control. 2024[...]

Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status

Lo Re V 3rd, Newcomb CW, Carbonari DM, Mezochow AK, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa[...]